newsfilter
← Earnings
Earnings Releases·

Revvity — Q3 2026 Earnings Summary

  • Q3 2026 revenue reached $729 million (up from $699 million YoY), with pro forma revenue at $710 million reflecting 7% growth; pro forma adjusted EPS rose to $1.37 from $1.13, while adjusted operating income margin expanded to 29.4% from 26.0%.
  • The company raised full-year 2026 guidance, forecasting pro forma revenue of approximately $2.86 billion, pro forma organic revenue growth of 5%, and pro forma adjusted EPS between $5.40 and $5.45.
  • Strategic capital allocation included $102.6 million in common stock purchases and $23.5 million in dividends over the first nine months, alongside the announced divestiture of the China Immunodiagnostics business (approx. 6% of FY2025 revenue) expected to close by end-2027.
  • Segment performance showed Life Sciences revenue growing 11% pro forma to $380 million, while Diagnostics revenue declined 2% to $349 million despite 5% pro forma organic growth.
Company
REVVITY INC
Sector
Healthcare
Industry
Diagnostics & Research